A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

Exclusion Criteria

• •With temperature \>37.0°C on axillary setting before vacciation;
• •With a medical history of diphtheria, pertussis or tetanus;
• •Had contact with individuals with confirmed pertussis, diphtheria and tetanus diseases in their families in the past 30 days;
• •Premature birth (delivery before the 37th week of pregnancy)or low birth weight (birth weight\< \<2500g);
• •History of dystocia, suffocation rescue, neurological damage;
• •With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
• •History of epilepsy, convulsions or convulsions, or have a family history of mental illness;
• •History of abnormal blood coagulation (such as coagulation factor deficiency, coagulopathy);
• •Had received immune enhancement or inhibitor therapy (continuous oral or instillation for more than 14 days);
• •History of severe allergic reactions to vaccination, such as difficulty breathing, urticaria;
• •Any prior administration of blood products in last 3 month;
• •Any prior administration of attenuated live vaccine in last 14 days;
• •Any prior administration of subunit or inactivated vaccines in last 7 days;
• •Plans to participate in or is participating in any other drug clinical study;
• •Has any other factors judged by investigators that make them unfit to participate in the clinical trial